Table 4. . Stereotactic radiotherapy: treatment and follow-up.
| Study (year) | BED10 | Total dose (Gy) | Fractions | Follow-up (mo) | Ref. |
|---|---|---|---|---|---|
| Hof et al. (2007) | ns | 12–30 | 1 | 14‡ (1.5–82) | [6] |
| Ricardi et al. (2011) | ns | 26–45 | 1–3 | 20.4‡ (3–77.4) | [83] |
| Zhang et al. (2011) | 79.2–132 | 36–60 | 3–5 | 24.7‡ (2.9–114.4) | [25] |
| Oh et al. (2012) | 100–150 | 50–60 | 4–5 | 21‡ (3–107) | [34] |
| Filippi et al. (2014) | 94–138 | 26 | 1 | 24‡ | [5] |
| Osti et al. (2013) | 76–120 | 23–30 | 1 | 15‡ (3–45) | [29] |
| Siva et al. (2015) | ns | (18–50) | 1–5 | 25‡ | [84] |
| Aoki et al. (2015) | 100 (85.5–120) | 50 (45–60) | 5 (5–9) | 31.7‡ (4.3–130) | [85] |
| Binkley et al. (2015) | 85 (50.4–151.2) | 25 (18–50) | ns | 22‡ (3–68) | [86] |
| Jung et al. (2015) | ns | 40–60 | 3–4 | 42.8‡ (11.0–104.1) | [87] |
| De Rose et al. (2016) | ns | 48–60 | 3–8 | 28.1‡ (5.4–104.5) | [88] |
| Kinj et al. (2016) | ns | 50–75 | 3–5 | 33‡ (4–85) | [33] |
| Helou et al. (2016) | ns | 48–52 | 4–5 | 22‡ (IQR 14–33) | [89] |
| Rieber et al. (2016) | 84.4 (22.5–180) | 12.5 (3–33) | 3 (1–13) | 14.3‡ (0–131.9) | [4] |
| Yamashita et al. (2016) | 105.6 (75.0–134.4) | ns | ns | 21‡ (1–119) | [90] |
| Franceschini et al. (2017) | ns | 30–60 | 1–8 | 24.2† (2.2–115.5) | [91] |
| Ricco et al. (2017) | 100 (IQR: 81–136) | 50 (IQR: 48–54) | 3 (IQR: 3–5) | 13‡ (IQR: 6–26) | [92] |
| Qiu et al. (2018) | ns | 40–60 | 5–11 | 6.4‡ | [93] |
Values expressed as number (fractions) or median (range) or range:
†
Mean.
‡
Median. Follow-up values expressed as months.
BED10: Biological effective dose; fr: Fraction; GTV: Gross tumor volume; Gy: Gray; IQR: Interquartile range; ns: Not stated; PTV: Planning tumor volume.